NCT06025396View on ClinicalTrials.gov

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

December 22, 2023

Study Completion Date

January 2, 2024

Conditions
Cocaine Use DisorderSubstance Use DisordersHealthy Volunteers
Interventions
DRUG

Cohort 1 - TMP-301

50 mg BID Fasted

DRUG

Placebo

Multiple ascending dose comparator

DRUG

Cohort 2 - TMP-301

50 mg QD Fasted

DRUG

Cohort 3 - TMP-301

50 mg QD Fed

DRUG

Cohort 4 - TMP-301

25 mg QD Fed

Trial Locations (1)

66212

Altasciences, Overland Park

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Tempero Bio, Inc.

INDUSTRY